Early changes in brain FDG metabolism during anticancer therapy in patients with pharyngeal cancer
Journal
Journal of Neuroimaging
Journal Volume
24
Journal Issue
3
Pages
266-272
Date Issued
2014
Abstract
BACKGROUND: The current study aimed to evaluate whether therapy-related changes occurred in brain metabolism at an earlier stage during the course of anticancer therapy. METHODS: We recruited 14 non-diabetic male patients with newly diagnosed pharyngeal squamous cell carcinoma. We analyzed the patients' serial brain FDG PET/CT scans by SPM8 to establish whether any therapy-related changes had occurred in brain FDG metabolism, either during or after the course of therapy. RESULTS: Decreased metabolism was noted during the anticancer therapy, displaying a symmetric pattern involving bilateral basal ganglia and bilateral occipital lobes. The decrease in FDG metabolism in these regions persisted after the anticancer therapy had terminated. However, relative recovery of the metabolism was noted in the bilateral occipital lobes, whereas further deterioration was noted in bilateral basal ganglia. CONCLUSIONS: The current study revealed that unappreciable changes in brain metabolism can occur during the early course of anticancer therapy, and persist even after therapy has terminated. Although the exact mechanism remains unclear, these changes may be related to the systemic effects of chemotherapy or radiotherapy as well as subclinical cancer-related depressive or adjustment mood disorder. ? 2013 by the American Society of Neuroimaging.
Subjects
Anticancer therapy; Brain FDG metabolism; Pharyngeal cancer
SDGs
Other Subjects
cetuximab; cisplatin; fluorodeoxyglucose; antineoplastic agent; fluorodeoxyglucose f 18; radiopharmaceutical agent; adult; aged; article; basal ganglion; brain metabolism; brain scintiscanning; cancer chemotherapy; cancer radiotherapy; cancer scintiscanning; clinical article; clinical evaluation; computer assisted emission tomography; data analysis software; drug effect; drug metabolism; head and neck squamous cell carcinoma; human; hypopharynx carcinoma; intensity modulated radiation therapy; male; middle aged; multileaf collimator; nasopharynx carcinoma; occipital lobe; oropharynx carcinoma; PET-CT scanner; pharyngeal squamous cell carcinoma; pharynx carcinoma; posterior cingulate; prefrontal cortex; radiation dose; whole body CT; whole body PET; antibody specificity; biological model; brain; Carcinoma, Squamous Cell; clinical trial; computer assisted diagnosis; computer simulation; diagnostic use; drug effects; early diagnosis; image enhancement; metabolic clearance rate; metabolism; Pharyngeal Neoplasms; procedures; reproducibility; scintiscanning; sensitivity and specificity; tissue distribution; Adult; Aged; Antineoplastic Agents; Brain; Carcinoma, Squamous Cell; Computer Simulation; Early Diagnosis; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Organ Specificity; Pharyngeal Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution
Type
journal article